In the present day we discuss an advance in an experimental mRNA vaccine for HIV, dive deep on Vinay Prasad’s sudden FDA departure, and extra.
The necessity-to-know this morning
Contained in the undoing of Vinay Prasad on the FDA
Vinay Prasad’s short-lived however polarizing run as head of the FDA’s biologics division ended simply 84 days in, after his aggressive push to tighten oversight on gene therapies and Covid-19 vaccines drew warmth from all sides — Trump allies, RFK Jr. loyalists, Democrats, and Duchenne affected person advocates.
His decision-making on Sarepta Therapeutics’ gene remedy— which he seen as backed by employees and rooted in security considerations — fueled political strain that solely mounted after far-right influencer Laura Loomer launched a marketing campaign highlighting his progressive leanings and previous anti-Trump feedback. A strong and intensely on-line regulator ran out of associates when it mattered most.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
